AstraZeneca and CSPC partner on AI drug research

June 13, 2025 09:12 AM PDT | By EODHD

Google News:

AstraZeneca and CSPC partner on AI drug research — Image source: Kalkine Media

Recent News

DoubleVerify Sees Update in Digital Ad Tech Sector Russell 1000

Pagaya Technologies PGY Gains Support Nasdaq Index Stocks Watch

Oceaneering International OII Sees Institutional Growth on NYSE Compos...

GAMMA Expands Stake in Valvoline Inc Amid Market Movements S&P 500

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN), the global biopharmaceutical company, has announced a strategic collaboration with CSPC Pharmaceuticals Group Limited, a company based in Shijiazhuang City, China. This partnership, disclosed in a recent 6-K filing with the Securities and Exchange Commission, is centered around the discovery and development of new oral treatment candidates through AI-enabled research. The collaboration is designed to target high-priority areas in drug discovery, with the goal of advancing the development of novel oral candidates that could potentially treat a range of diseases across multiple indications. This includes a pre-clinical small molecule oral therapy for immunological diseases. Sharon Barr, AstraZeneca (NASDAQ:AZN)’s Executive Vice President and Head of BioPharmaceuticals R&D, emphasized the significance of the partnership in accelerating the discovery of innovative therapeutic molecules to address chronic diseases affecting over two billion people worldwide.

CSPC will conduct the research using their AI-driven drug discovery platform, which harnesses artificial intelligence to analyze the binding patterns of target proteins with compound molecules, thereby facilitating the optimization and selection of effective small molecules with promising developability. Financially, CSPC stands to gain an upfront payment of $110 million from AstraZeneca. Additionally, CSPC could receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments, along with potential single-digit royalties on annual net sales of the products. AstraZeneca retains the rights to exercise options for exclusive licenses to develop and commercialize worldwide candidates identified under this agreement. This collaboration builds on AstraZeneca’s ongoing commitment to innovation in China, following a substantial $2.5 billion investment in Beijing announced earlier in 2025.

The partnership aligns with AstraZeneca’s focus on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The information provided in this article is based on a press release statement. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.